Incontinence implants set to enter US trials:
This article was originally published in Clinica
An injectable treatment for female stress incontinence, which has been available in Europe for eight years, is set to undergo clinical trials in the US in the autumn. The FDA has granted Minneapolis, Minnesota-based Uroplasty an investigational device exemption for its Macroplastique implant, which is injected into the tissue surrounding the urethra as a bulking agent to enhance sphincter function. It is also used outside the US for incontinence in men after prostate surgery and vesicoureteral reflux in children.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.